For research use only. Not for therapeutic Use.
CBR-470-2, a glycine-substituted analog, can activate NRF2 signaling. CBR-470-2 can be used for the research of modulation glycolysis[1].
CBR-470-2 (1-10 μM; 24 h) increases transcript levels of the NRF2-responsive genes NQO1 and HMOX1 in epidermal keratinocytes and dermal fibroblasts[1].
CBR-470-2 (50 mg/kg; p.o. twice daily for 10 d) induces activation of NRF2 signaling in vivo[1].
| Catalog Number | I045351 |
| CAS Number | 2416095-00-4 |
| Synonyms | 2-[[(3S,4R)-4-(3,4-dichlorophenyl)sulfonyl-1,1-dioxothiolan-3-yl]amino]acetic acid |
| Molecular Formula | C12H13Cl2NO6S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C12H13Cl2NO6S2/c13-8-2-1-7(3-9(8)14)23(20,21)11-6-22(18,19)5-10(11)15-4-12(16)17/h1-3,10-11,15H,4-6H2,(H,16,17)/t10-,11-/m0/s1 |
| InChIKey | FNQDSYKGBCVHHI-QWRGUYRKSA-N |
| SMILES | C1C(C(CS1(=O)=O)S(=O)(=O)C2=CC(=C(C=C2)Cl)Cl)NCC(=O)O |
| Reference | [1]. Bollong MJ, et, al. A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling. Nature. 2018 Oct;562(7728):600-604. |
